BG104689A - Pharmaceutical preparations for selectively supplementing oestrogen deficiency in the central nervous system - Google Patents

Pharmaceutical preparations for selectively supplementing oestrogen deficiency in the central nervous system

Info

Publication number
BG104689A
BG104689A BG104689A BG10468900A BG104689A BG 104689 A BG104689 A BG 104689A BG 104689 A BG104689 A BG 104689A BG 10468900 A BG10468900 A BG 10468900A BG 104689 A BG104689 A BG 104689A
Authority
BG
Bulgaria
Prior art keywords
central nervous
oestrogen
transcription
nervous system
estradiol
Prior art date
Application number
BG104689A
Other languages
Bulgarian (bg)
English (en)
Inventor
Vladimir Patchev
Michael Oettel
Ina Thieme
Sigfrid Schwarz
Wolfgang Romer
Original Assignee
Jenapharm Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1998121831 external-priority patent/DE19821831A1/de
Application filed by Jenapharm Gmbh & Co. Kg filed Critical Jenapharm Gmbh & Co. Kg
Publication of BG104689A publication Critical patent/BG104689A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BG104689A 1998-02-20 2000-08-15 Pharmaceutical preparations for selectively supplementing oestrogen deficiency in the central nervous system BG104689A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19807264 1998-02-20
DE1998121831 DE19821831A1 (de) 1998-05-15 1998-05-15 Pharmazeutische Präparate zur gezielten Substitution des Estrogenmangels im Zentralnervensystem
PCT/DE1999/000353 WO1999042108A1 (de) 1998-02-20 1999-02-10 Pharmazeutische präparate zur gezielten substitution des estrogenmangels im zentralnervensystem

Publications (1)

Publication Number Publication Date
BG104689A true BG104689A (en) 2001-04-30

Family

ID=26044035

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104689A BG104689A (en) 1998-02-20 2000-08-15 Pharmaceutical preparations for selectively supplementing oestrogen deficiency in the central nervous system

Country Status (24)

Country Link
EP (1) EP1056460B1 (tr)
JP (1) JP2002503694A (tr)
KR (1) KR20010041107A (tr)
CN (1) CN1291102A (tr)
AT (1) ATE252388T1 (tr)
AU (1) AU739071C (tr)
BG (1) BG104689A (tr)
BR (1) BR9909205A (tr)
CA (1) CA2321498A1 (tr)
CZ (1) CZ291764B6 (tr)
DE (1) DE59907446D1 (tr)
EA (1) EA002707B1 (tr)
EE (1) EE03906B1 (tr)
HU (1) HUP0100742A3 (tr)
ID (1) ID27069A (tr)
IL (1) IL137727A0 (tr)
IS (1) IS5571A (tr)
NO (1) NO20004153L (tr)
NZ (1) NZ506049A (tr)
PL (1) PL342313A1 (tr)
SK (1) SK12152000A3 (tr)
TR (1) TR200002400T2 (tr)
UA (1) UA57830C2 (tr)
WO (1) WO1999042108A1 (tr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1310799B1 (en) * 2001-11-07 2005-12-21 Schering AG In vitro screening for ligands of the estrogen receptor
CN112189624A (zh) * 2020-09-08 2021-01-08 山东第一医科大学(山东省医学科学院) 一种利用受体基因沉默技术构建和鉴定女性ad模型的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4791099A (en) * 1984-10-29 1988-12-13 Chaovanee Aroonsakul Method of treatment for central nervous system diseases such as Alzheimer's's disease
US4897389A (en) * 1984-10-29 1990-01-30 Chaovanee Aroonsakul Treating central nervous system diseases
DE4239946C2 (de) * 1992-11-27 2001-09-13 Jenapharm Gmbh Estranderivate mit einer 14alpha,15alpha-Methylengruppe und Verfahren zu ihrer Herstellung
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
DE4338314C1 (de) * 1993-11-10 1995-03-30 Jenapharm Gmbh Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen
DE4429397C2 (de) * 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE19524937A1 (de) * 1995-07-08 1997-01-09 Jenapharm Gmbh Pharmazeutische Präparate zur Prophylaxe und Therapie radikalvermittelter Zellschädigungen und zur medikamentösen Substitution beim Mann
JPH11510144A (ja) * 1995-07-24 1999-09-07 ユニバーシティー・オブ・フロリダ・リサーチ・ファンデーション・インコーポレーテッド 細胞に神経保護を付与するための薬剤の製造のための非エストロゲン多環式フェノール化合物の使用

Also Published As

Publication number Publication date
BR9909205A (pt) 2000-11-14
CZ20002938A3 (cs) 2001-01-17
NO20004153L (no) 2000-10-09
IS5571A (is) 2000-07-24
TR200002400T2 (tr) 2000-11-21
CA2321498A1 (en) 1999-08-26
UA57830C2 (uk) 2003-07-15
HUP0100742A3 (en) 2002-07-29
EA002707B1 (ru) 2002-08-29
NO20004153D0 (no) 2000-08-18
PL342313A1 (en) 2001-06-04
WO1999042108A1 (de) 1999-08-26
ID27069A (id) 2001-02-22
AU739071C (en) 2002-04-11
EE200000477A (et) 2001-12-17
AU2920999A (en) 1999-09-06
EP1056460B1 (de) 2003-10-22
ATE252388T1 (de) 2003-11-15
JP2002503694A (ja) 2002-02-05
EE03906B1 (et) 2002-12-16
HUP0100742A2 (hu) 2001-09-28
KR20010041107A (ko) 2001-05-15
EP1056460A1 (de) 2000-12-06
IL137727A0 (en) 2001-10-31
CZ291764B6 (cs) 2003-05-14
DE59907446D1 (de) 2003-11-27
EA200000858A1 (ru) 2001-04-23
AU739071B2 (en) 2001-10-04
NZ506049A (en) 2002-09-27
CN1291102A (zh) 2001-04-11
SK12152000A3 (sk) 2001-02-12

Similar Documents

Publication Publication Date Title
WO1998027929A3 (de) Therapeutische gestagene zur behandlung von premenstrual dysphoric disorder
WO1996019568A3 (en) Stabilized ribozyme analogs
HUP0102483A2 (hu) Androszt-5-én-3béta, 17béta-diolt tartalmazó gyógyszerkészítmények
MX9700223A (es) Composicion farmaceutica para la liberacion controlada de moguisteina en una suspension liquida.
PL323046A1 (en) Procedures related to arterio-vascular and vascular transplants: method and compositions
CA2337991A1 (en) Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents
ATE235907T1 (de) Verwendung von kompetitiven progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen
NZ271363A (en) Use of antiglucocorticoid steroids to treat anxiety disorders
MY137435A (en) Retinoid compounds (i)
NZ333232A (en) Use of p-aminophenol derivatives (paracetamol) to treat neurodegenerative disease
BG102660A (en) Combined pharmaceutical preparation of lhrh-analogues and antiesterogens for the treatment of gynaecological disorders
BG104689A (en) Pharmaceutical preparations for selectively supplementing oestrogen deficiency in the central nervous system
GR3025872T3 (en) Orally active derivatives of 1,3,5(10)-estratriene
MX9800049A (es) Antraquinonas mono- y disulfo-substituidas y su uso para el tratamiento de trastornos de la matriz del hueso.
EP0743068A3 (en) Composition for inhibiting bone loss containing vanadyl sulfate
WO1994024279A3 (en) Agents for the prevention and treatment of huntington's disease and other neurological disorders
AU8624198A (en) 11beta-aryl substituted 14,17-ethano-oestratriens, method for the production of these compounds and their use in the production of medicaments.
CA2421302A1 (en) 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds
ATE212352T1 (de) Ungesättigte 14,15-cyclopropano-androstane, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische präparate
Romanenkova Regional demographic policy: goals, principles, possible solutions
MX9800697A (es) Uso de glicosidos de calendula para el tratamiento de psoriasis.